Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Annual review of KRAS inhibitors in 2022.

European journal of medicinal chemistry - 5 Mar 2023

Wang Hao, Chi Lingling, Yu Fuqiang, Dai Honglin, Gao Chao, Si Xiaojie, Wang Zhengjie, Liu Limin, Zheng Jiaxin, Shan Lihong, Liu Hongmin, Zhang Qiurong

Abstract excerpt

Kirsten rat sarcoma viral (KRAS) oncogene is the most commonly mutated isoform of RAS, accounting for 85% of RAS-driven human cancers. KRAS functioning as a signaling hub participates in multiple cellular signaling pathways and regulates a variety of critical processes such as cell proliferation, differentiation, growth, metabolism and migration. Over the past decades, KRAS oncoprotein has been considered as an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Differentiation
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 36680986
DOI: 10.1016/j.ejmech.2023.115124

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Annual review of KRAS inhibitors in 2022.PMID 36680986Read ↗

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.Semantic proximity Read ↗

Inhibition of GTPase KRASG12D: a review of patent literature.Semantic proximity Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read ↗

Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021).Semantic proximity Read ↗

From bench to bedside: current development and emerging trend of KRAS-targeted therapy.Semantic proximity Read ↗

Drugging KRAS: current perspectives and state-of-art review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.